Monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and the programmed death-1 (PD-1) receptor and its ligand programmed death-ligand 1 (PD-L1) have been approved as the standard of care in different tumor sites. This evidence concerns the gene CTLA4 and neoplasm.